TY - JOUR
T1 - Multi-institutional comparison of secondary check of treatment planning using computer-based independent dose calculation for non-C-arm linear accelerators
AU - Tachibana, Hidenobu
AU - Uchida, Yukihiro
AU - Miyakawa, Ryuta
AU - Yamashita, Mikiko
AU - Sato, Aya
AU - Kito, Satoshi
AU - Maruyama, Daiki
AU - Noda, Shigetoshi
AU - Kojima, Toru
AU - Fukuma, Hiroshi
AU - Shirata, Ryosuke
AU - Okamoto, Hiroyuki
AU - Nakamura, Mitsuhiro
AU - Takada, Yuma
AU - Nagata, Hironori
AU - Hayashi, Naoki
AU - Takahashi, Ryo
AU - Kawai, Daisuke
AU - Itano, Masanobu
N1 - Publisher Copyright:
© 2018 Associazione Italiana di Fisica Medica
PY - 2018/12
Y1 - 2018/12
N2 - Purpose: This report covers the first multi-institutional study of independent monitor unit (MU)/dose calculation verification for the CyberKnife, Vero4DRT, and TomoTherapy radiotherapy delivery systems. Methods: A total of 973 clinical treatment plans were collected from 12 institutions. Commercial software employing the Clarkson algorithm was used for verification after a measurement validation study, and the doses from the treatment planning systems (TPSs) and verification programs were compared on the basis of the mean value ± two standard deviations. The impact of heterogeneous conditions was assessed in two types of sites: non-lung and lung. Results: The dose difference for all locations was 0.5 ± 7.2%. There was a statistically significant difference (P < 0.01) in dose difference between non-lung (−0.3 ± 4.4%) and lung sites (3.5 ± 6.7%). Inter-institutional comparisons showed that various systematic differences were associated with the proportion of different treatment sites and heterogeneity correction. Conclusions: This multi-institutional comparison should help to determine the departmental action levels for CyberKnife, Vero4DRT, and TomoTherapy, as patient populations and treatment sites may vary between the modalities. An action level of ±5% could be considered for intensity-modulated radiation therapy (IMRT), non-IMRT, and volumetric modulated arc radiotherapy using these modalities in homogenous and heterogeneous conditions with a large treatment field applied to a large region of homogeneous media. There were larger systematic differences in heterogeneous conditions with a small treatment field because of differences in heterogeneity correction with the different dose calculation algorithms of the primary TPS and verification program.
AB - Purpose: This report covers the first multi-institutional study of independent monitor unit (MU)/dose calculation verification for the CyberKnife, Vero4DRT, and TomoTherapy radiotherapy delivery systems. Methods: A total of 973 clinical treatment plans were collected from 12 institutions. Commercial software employing the Clarkson algorithm was used for verification after a measurement validation study, and the doses from the treatment planning systems (TPSs) and verification programs were compared on the basis of the mean value ± two standard deviations. The impact of heterogeneous conditions was assessed in two types of sites: non-lung and lung. Results: The dose difference for all locations was 0.5 ± 7.2%. There was a statistically significant difference (P < 0.01) in dose difference between non-lung (−0.3 ± 4.4%) and lung sites (3.5 ± 6.7%). Inter-institutional comparisons showed that various systematic differences were associated with the proportion of different treatment sites and heterogeneity correction. Conclusions: This multi-institutional comparison should help to determine the departmental action levels for CyberKnife, Vero4DRT, and TomoTherapy, as patient populations and treatment sites may vary between the modalities. An action level of ±5% could be considered for intensity-modulated radiation therapy (IMRT), non-IMRT, and volumetric modulated arc radiotherapy using these modalities in homogenous and heterogeneous conditions with a large treatment field applied to a large region of homogeneous media. There were larger systematic differences in heterogeneous conditions with a small treatment field because of differences in heterogeneity correction with the different dose calculation algorithms of the primary TPS and verification program.
UR - http://www.scopus.com/inward/record.url?scp=85056916203&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85056916203&partnerID=8YFLogxK
U2 - 10.1016/j.ejmp.2018.11.011
DO - 10.1016/j.ejmp.2018.11.011
M3 - Article
C2 - 30527090
AN - SCOPUS:85056916203
SN - 1120-1797
VL - 56
SP - 58
EP - 65
JO - Physica Medica
JF - Physica Medica
ER -